Serotonin: A different player in hypertension-associated thrombosis

Hypertension

Volumn 65, Issue 5, 2015, Pages 942-948

  Fraer, Mony ^a   Kilic, Fusun ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; SEROTONIN;

CELL ADHESION; DISEASE ASSOCIATION; FLUORESCENCE ACTIVATED CELL SORTING; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOSIS; ANIMAL; BLOOD; COMPLICATION; HUMAN;

ANIMALS; HUMANS; HYPERTENSION; PLATELET AGGREGATION; SEROTONIN; THROMBOSIS;

EID: 84937418494     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.05061     Document Type: Review

References (69)

1. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132: 397-414. doi: 10.1053/j.gastro.2006.11.002
2. Côté F, Thévenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vodjdani G. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci U S A. 2003; 100: 13525-13530. doi: 10.1073/pnas.2233056100
3. Walther DJ, Peter JU, Bashammakh S, Hörtnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003; 299: 76. doi: 10.1126/science.1078197
4. Talvenheimo J, Nelson PJ, Rudnick G. Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport. J Biol Chem. 1979; 254: 4631-4635
5. Holmsen H, Weiss HJ. Secretable storage pools in platelets. Annu Rev Med. 1979; 30: 119-134. doi: 10.1146/annurev.me.30.020179.001003
6. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res. 1999; 95: 1-18
7. Lauder JM, Tamir H, Sadler TW. Serotonin and morphogenesis. I. Sites of serotonin uptake and -binding protein immunoreactivity in the midgestation mouse embryo. Development. 1988; 102: 709-720
8. Côté F, Fligny C, Bayard E, Launay JM, Gershon MD, Mallet J, Vodjdani G. Maternal serotonin is crucial for murine embryonic development. Proc Natl Acad Sci U S A. 2007; 104: 329-334. doi: 10.1073/pnas.0606722104
9. Shirakawa R, Yoshioka A, Horiuchi H, Nishioka H, Tabuchi A, Kita T. Small GTPase Rab4 regulates Ca2+-induced alpha-granule secretion in platelets. J Biol Chem. 2000; 275: 33844-33849. doi: 10.1074/jbc. M002834200
10. Crosby D, Poole AW. Platelet dense-granule secretion: the [3H]-5-HT secretion assay. Methods Mol Biol. 2004; 272: 95-96. doi: 10.1385/1-59259-782-3: 095
11. Mercado CP, Quintero MV, Li Y, Singh P, Byrd AK, Talabnin K, Ishihara M, Azadi P, Rusch NJ, Kuberan B, Maroteaux L, Kilic F. A serotonininduced N-glycan switch regulates platelet aggregation. Sci Rep. 2013; 3: 2795. doi: 10.1038/srep02795
12. Ziu E, Mercado CP, Li Y, Singh P, Ahmed BA, Freyaldenhoven S, Lensing S, Ware J, Kilic F. Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-Thrombotic effect of serotonin. J Mol Cell Cardiol. 2012; 52: 1112-1121. doi: 10.1016/j.yjmcc.2012.02.004
13. Przyklenk K, Frelinger AL III, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010; 8: 331-340. doi: 10.1111/j.1538-7836.2009.03693.x.
14. Walther DJ, Peter JU, Winter S, Höltje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, Bader M. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell. 2003; 115: 851-862
15. Mercado CP, Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv. 2010; 10: 231-241. doi: 10.1124/mi.10.4.6
16. Singh P, Fletcher TW, Li Y, Rusch NJ, Kilic F. Serotonin uptake rates in platelets from angiotensin II-induced hypertensive mice. Health (Irvine Calif). 2013; 5(4A): 31-39. doi: 10.4236/health.2013.54A005
17. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999; 104: 1731-1737. doi: 10.1172/JCI8399
18. Brass LF. More pieces of the platelet activation puzzle slide into place. J Clin Invest. 1999; 104: 1663-1665. doi: 10.1172/JCI8944
19. Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R, Eto T, Asada Y. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost. 2006; 4: 247-255. doi: 10.1111/j.1538-7836.2005.01702.x.
20. Van Den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation. 1989; 79: 116-124
21. Pietraszek MH, Takada Y, Takada A, Fujita M, Watanabe I, Taminato A, Yoshimi T. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res. 1992; 66: 765-774
22. Saxena PR, Villalón CM. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol. 1990; 15 Suppl 7: S17-S34
23. Karras DJ, Ufberg JW, Heilpern KL, Cienki JJ, Chiang WK, Wald MM, Harrigan RA, Wald DA, Shayne P, Gaughan J, Kruus LK. Elevated blood pressure in urban emergency department patients. Acad Emerg Med. 2005; 12: 835-843. doi: 10.1197/j.aem.2005.04.015
24. Vanhoutte PM. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol. 1991; 17 Suppl 5: S6-S12
25. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation. 1990; 81: 1762-1767
26. Berry CN, Lorrain J, Lochot S, Delahaye M, Lalé A, Savi P, Lechaire I, Ferrari P, Bernat A, Schaeffer P, Janiak P, Duval N, Grosset A, Herbert JM, O'Connor SE. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost. 2001; 85: 521-528
27. Ottervanger JP, Stricker BH, Huls J, Weeda JN. Bleeding attributed to the intake of paroxetine. Am J Psychiatry. 1994; 151: 781-782
28. Ahmed BA, Jeffus BC, Bukhari SI, Harney JT, Unal R, Lupashin VV, Van Der Sluijs P, Kilic F. Serotonin transamidates Rab4 and facilitates its binding to the C terminus of serotonin transporter. J Biol Chem. 2008; 283: 9388-9398. doi: 10.1074/jbc.M706367200
29. Mercado CP, Ziu E, Kilic F. Communication between 5-HT and small GTPases. Curr Opin Pharmacol. 2011; 11: 23-28. doi: 10.1016/j. coph.2011.01.006
30. Tang DD, Bai Y, Gunst SJ. Silencing of p21-Activated kinase attenuates vimentin phosphorylation on Ser-56 and reorientation of the vimentin network during stimulation of smooth muscle cells by 5-hydroxytryptamine. Biochem J. 2005; 388(Pt 3): 773-783. doi: 10.1042/BJ20050065
31. Li QF, Spinelli AM, Wang R, Anfinogenova Y, Singer HA, Tang DD. Critical role of vimentin phosphorylation at Ser-56 by p21-Activated kinase in vimentin cytoskeleton signaling. J Biol Chem. 2006; 281: 34716-34724. doi: 10.1074/jbc.M607715200
32. Ahmed BA, Bukhari IA, Jeffus BC, Harney JT, Thyparambil S, Ziu E, Fraer M, Rusch NJ, Zimniak P, Lupashin V, Tang D, Kilic F. The cellular distribution of serotonin transporter is impeded on serotonin-Altered vimentin network. PLoS One. 2009; 4: e4730. doi: 10.1371/journal. pone.0004730
33. Duerschmied D, Canault M, Lievens D, Brill A, Cifuni SM, Bader M, Wagner DD. Serotonin stimulates platelet receptor shedding by tumor necrosis factor-Alpha-converting enzyme (ADAM17). J Thromb Haemost. 2009; 7: 1163-1171. doi: 10.1111/j.1538-7836.2009.03476.x.
34. Tschopp TB, Baumgartner HR. Defective platelet adhesion and aggregation on subendothelium exposed in vivo or in vitro to flowing blood of fawn-hooded rats and storage pool disease. Thromb Haemost. 1977; 38: 620-629
35. Raymond SL, Dodds WJ. Characterization of the fawn-hooded rat as a model for hemostatic studies. Thromb Diath Haemorrh. 1975; 33: 361-369
36. Magro A, Bizios R, Catalfamo J, Blumenstock F, Rudofsky U. Collageninduced rat platelet reactivity is enhanced in whole blood in both the presence and absence of dense granule secretion. Thromb Res. 1992; 68: 345-356
37. Kirchmaier CM, Meyer M, Spangenberg P, Heller R, Haroske D, Breddin HK, Till U. Platelet membrane defects in fawn hooded bleeder rats. Thromb Res. 1990; 57: 353-360
38. Kelm S, Schauer R. Sialic acids in molecular and cellular interactions. Int Rev Cytol. 1997; 175: 137-240
39. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem. 2007; 102: 206-215. doi: 10.1111/j.1471-4159.2007.04542.x.
40. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999; 100: 483-489
41. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension. 1999; 33: 1353-1358
42. Biondi ML, Agostoni A, Marasini B. Serotonin levels in hypertension. J Hypertens Suppl. 1986; 4: S39-S41
43. Davis RP, Szasz T, Garver H, Burnett R, Tykocki NR, Watts SW. Onemonth serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat. ACS Chem Neurosci. 2013; 4: 141-148. doi: 10.1021/cn300114a.
44. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem. 1948; 176: 1243-1251
45. Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert M, Fadel E, Adnot S, Loirand G, Pacaud P. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009; 179: 1151-1158. doi: 10.1164/ rccm.200805-691OC
46. Ziu E, Hadden C, Li Y, Lowery CL III, Singh P, Ucer SS, Mercado CP, Gu HH, Kilic F. Effect of serotonin on platelet function in cocaine exposed blood. Sci Rep. 2014; 4: 5945. doi: 10.1038/srep05945
47. Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan M, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Santonastaso CL, Lechi A, Patrono C. Determinants of platelet activation in human essential hypertension. Hypertension. 2004; 43: 64-70. doi: 10.1161/01.HYP.0000105109.44620.1B.
48. Menon DV, Wang Z, Fadel PJ, Arbique D, Leonard D, Li JL, Victor RG, Vongpatanasin W. Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J Am Coll Cardiol. 2007; 50: 626-633. doi: 10.1016/j.jacc.2007.03.060
49. Eisenberg MJ, Mendelson J, Evans GT Jr, Jue J, Jones RT, Schiller NB. Left ventricular function immediately after intravenous cocaine: a quantitative two-dimensional echocardiographic study. J Am Coll Cardiol. 1993; 22: 1581-1586
50. Senchenkova EY, Russell J, Almeida-Paula LD, Harding JW, Granger DN. Angiotensin II-mediated microvascular thrombosis. Hypertension. 2010; 56: 1089-1095. doi: 10.1161/HYPERTENSIONAHA.110.158220
51. Kugelmass AD, Oda A, Monahan K, Cabral C, Ware JA. Activation of human platelets by cocaine. Circulation. 1993; 88: 876-883
52. Kolodgie FD, Virmani R, Cornhill JF, Herderick EE, Smialek J. Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-Associated coronary vasospasm and thrombosis. J Am Coll Cardiol. 1991; 17: 1553-1560
53. Moliterno DJ, Lange RA, Gerard RD, Willard JE, Lackner C, Hillis LD. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. Am J Med. 1994; 96: 492-496
54. Heesch CM, Wilhelm CR, Ristich J, Adnane J, Bontempo FA, Wagner WR. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000; 83: 688-695
55. Rinder HM, Ault KA, Jatlow PI, Kosten TR, Smith BR. Platelet alphagranule release in cocaine users. Circulation. 1994; 90: 1162-1167
56. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T, Han DD, Gu HH. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci U S A. 2006; 103: 9333-9338. doi: 10.1073/pnas.0600905103
57. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002; 40: 521-527
58. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med. 2000; 45: 419-429
59. Unger T, Culman J, Gohlke P. (Ang II receptor blockade and endorgan protection: pharmacological rationale and evidence. J Hypertens. 1998; 16: S3-S9
60. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res. 2007; 101: 654-662. doi: 10.1161/ CIRCRESAHA.107.158410
61. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens. 1998; 16: 447-456
62. Muthalif MM, Karzoun NA, Gaber L, Khandekar Z, Benter IF, Saeed AE, Parmentier JH, Estes A, Malik KU. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-Activated protein kinase and cytochrome P450 metabolites. Hypertension. 2000; 36: 604-609
63. Rosenblum WI, el-Sabban F, Hirsh PD. Angiotensin delays platelet aggregation after injury of cerebral arterioles. Stroke. 1986; 17: 1203-1205
64. Iizuka K, Hamaue N, Machida T, Hirafuji M, Tsuji M. Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009; 34: 18-30. doi: 10.1080/07435800902889685
65. Nakamura K, Kariyazono H, Moriyama Y, Toyohira H, Kubo H, Yotsumoto G, Taira A, Yamada K. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin. Blood Coagul Fibrinolysis. 1999; 10: 513-519
66. Villalón CM, Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007; 376: 45-63. doi: 10.1007/s00210-007-0179-1
67. Shen FM, Wang J, Ni CR, Yu JG, Wang WZ, Su DF. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors. Clin Exp Pharmacol Physiol. 2007; 34: 702-707. doi: 10.1111/j.1440-1681.2007.04626.x.
68. Buch J. Urapidil, a dual-Acting antihypertensive agent: Current usage considerations. Adv Ther. 2010; 27: 426-443. doi: 10.1007/ s12325-010-0039-0
69. Southwick SM, Paige S, Morgan CA III, Bremner JD, Krystal JH, Charney DS. Neurotransmitter alterations in PTSD: catecholamines and serotonin. Semin Clin Neuropsychiatry. 1999; 4: 242-248. doi: 10.153/SCNP00400242